Lupin Delivers On Generic Fostair With UK Luforbec Launch
UK’s NHS Spends Around $250m Per Year On Asthma And COPD Treatment
Executive Summary
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.
You may also be interested in...
Lupin Lines Up A Pair Of US Launches
India’s Lupin has launched its droxidopa rival to Northera in the US, in 100mg, 200mg and 300mg strengths. The company also launched the generic version of Horizon’s Duexis ibuprofen/famotidine 800mg/26.6mg tablets.
Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
Stada’s Thornton & Ross Rivals Seretide In UK
Stada’s Thornton & Ross UK subsidiary has launched a generic version of Seretide, known as Advair in the US, marking its first push into the respiratory arena.